Twist Bioscience Corp vs VanEck Vietnam ETF — how do they compare? Twist Bioscience Corp trades at $125.52 (market cap $8.42B), while VanEck Vietnam ETF trades at $17.85. The key difference: Twist Bioscience Corp is trading nearer its 52-week high, VanEck Vietnam ETF nearer its low. Which is the better fit depends on your goals.
| TWST | VNM | |
|---|---|---|
Market Cap | $8.42B | — |
Sector | Health | Sector/Thematic |
52-Week High | $153.10 | $19.80 |
52-Week Low | $24.16 | $16.34 |
Enterprise Value | $8.35B | — |
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
VNM trades at $17.91, down 1.38% for the day, with a technical outlook leaning bearish based on moving averages. The ETF's performance is challenged by its heavy concentration in Vietnamese real estate and financials, exposing it to sector-specific volatility. Recent news highlights underperformance relative to other emerging markets, though potential exists from FTSE Russell's upcoming EM reclassification in September 2026, which may attract foreign institutional flows.
The outlook remains cautious due to near-term headwinds from sector concentration and macroeconomic factors in Vietnam. Investment opportunity hinges on the country's long-term growth trajectory and potential inflows from index changes, but risks from interest rate sensitivity and concentrated holdings warrant careful consideration for investors seeking emerging market exposure.
Trailing returns across standard periods
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →